Fig. 1From: Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in AustriaCalibration of cervical cancer HPV incidence related to types 16, 18, 6, 11, 31, 33, 45, 52, and 58Back to article page